Journal profile · PHARMACOLOGY & PHARMACY
Drugs-Real World Outcomes
ISSN 2199-1154 · eISSN 2198-9788 · Springer Nature · United Kingdom
Drugs-Real World Outcomes: CAS Zone 4 · Medicine (2025 upgraded edition); impact factor 2 (journal website); fully open access; APC about USD 3,190; review about 8 weeks (community reports); 61 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Drugs-Real World Outcomes is published by Springer Nature and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Pharmacovigilance and Adverse Drug Reactions, Pharmaceutical Practices and Patient Outcomes and Medication Adherence and Compliance, together about 35.6% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
Drugs - Real World Outcomes targets original research and definitive reviews regarding the use of real-world data to evaluate health outcomes and inform healthcare decision-making on drugs, devices and other interventions in clinical practice. The journal includes, but is not limited to, the following research areas: Using registries/databases/health records and other non-selected observational datasets to investigate: drug use and treatment outcomes prescription patterns drug safety signals adherence to treatment guidelines benefit : risk profiles comparative effectiveness economic analyses including cost-of-illness Data-driven research methodologies, including the capture, curation, search, sharing, analysis and interpretation of ‘big data’ Techniques and approaches to optimise real-world modelling.
From the journal's Aims & Scope
Research area (LetPub): PHARMACOLOGY & PHARMACY
Editor-in-chief Sophie StevensonPublisher website
Editorial board by country: none in mainland China; most named United States 12, Japan 5, Australia 3, Spain 2, Netherlands 2 (39 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Pharmacovigilance and Adverse Drug ReactionsPharmacology, Toxicology and Pharmaceutics14.1%
- Pharmaceutical Practices and Patient OutcomesMedicine13%
- Medication Adherence and ComplianceMedicine8.5%
- Heart Failure Treatment and ManagementMedicine4.4%
- Rheumatoid Arthritis Research and TherapiesMedicine3.9%
- Antibiotic Use and ResistanceImmunology and Microbiology3.9%
- Schizophrenia research and treatmentMedicine3.6%
- Atrial Fibrillation Management and OutcomesMedicine3.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Pharmacology & Pharmacy | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
EmbasePublisher website
Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 2Publisher website ·
- 5-year impact factor (publisher) 2025
- 2.1Publisher website ·
- CiteScore 2026-06
- 3.9LetPub ·
- SJR 2026-06
- 0.66LetPub ·
- SNIP 2026-06
- 0.89LetPub ·
- h-index
- 33OpenAlex ·
- i10-index
- 191OpenAlex ·
- 2-year mean citedness
- 2.45OpenAlex ·
- Self-citation rate
- 5%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 56LetPub ·
- Downloads per year (publisher) 2025
- 453,600Publisher website ·
Articles by year OpenAlex count · 572 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 48 | 48 | 10 |
| 2025 | 61 | 61 | 84 |
| 2024 | 63 | 63 | 327 |
| 2023 | 61 | 61 | 344 |
| 2022 | 60 | 60 | 626 |
| 2021 | 61 | 61 | 769 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
Too few articlesOnly 1 articles from the last 24 months carry both submission and acceptance dates, too few for a median
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 8 weeksLetPub ·
- Submission to first decision
- 6 daysPublisher website ·
- Submission to publication (journal-reported)
- about 8 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | EUR 2,690 / USD 3,190 / GBP 2,390 | Yes | CC BY-NC | |
| OpenAlex | USD 3,090 / EUR 2,590 / GBP 2,290 | — | — | |
| LetPub | GBP 2,090 / USD 2,890 / EUR 2,390 | Yes | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare4 items from the author guidelines
- Abstract
- 150–250 words
- Manuscript length
- ≤ 10,000 words
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
Article types accepted10
- case reportPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- editorialInternal Review by Editorial Staff: The journal editor will perform an initial appraisal of each manuscript. If your paper has been peer reviewed by another jou…Length not stated
- letter to the editorPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- original researchPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- original research articlePlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- research articlePlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- reviewPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- review articlePlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- short communicationPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
- systematic reviewPlease note: There is no limit on the number of tables, figures or references that can accompany an article. Information that is relevant but not critical to un…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, License & copyright, Open access, Trial registration / reporting guidelines
- AI use Generative AI Images
Please check Springer’s policy on generative AI images and make sure your work adheres to the principles described therein. Back to top
Source ↗Publisher website ·- Authorship Authorship Principles
These guidelines describe authorship principles and good authorship practices to which prospective authors should adhere to. Authorship clarified The Journal and Publisher assume all authors agreed with the content and that all gave explicit consent to submit and that they obtained consent from the responsible authorities at the institute/organization where the work has been carried out, before th…
Source ↗Publisher website ·- Conflicts of interest Disclosures and declarations
All authors are requested to include information regarding sources of funding, financial or non-financial interests, study-specific approval by the appropriate ethics committee for research involving humans and/or animals, informed consent if the research involved human participants, and a statement on welfare of animals if the research involved animals (as appropriate). The decision whether such …
Source ↗Publisher website ·- Data availability Data availability statements
All original research must include a data availability statement. This statement should explain how to access data supporting the results and analysis in the article, including links/citations to publicly archived datasets analysed or generated during the study. Please see our full policy here. If it is not possible to share research data publicly, for instance when individual privacy could be com…
Source ↗Publisher website ·- License & copyright Copyright
In confirming the publication of your article with open access you agree to the Creative Commons Attribution Non-Commercial License 4.0 International License Find more about the license agreement Back to top
Source ↗Publisher website ·- Open access Open access publishing
To find out more about publishing your work Open Access in Drugs - Real World Outcomes, including information on fees, funding and licences, visit our Open access publishing page. Back to top
Source ↗Publisher website ·- Trial registration / reporting guidelines Clinical Trial Registration
The World Health Organization (WHO) definition of a clinical trial is "any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes". The WHO defines health interventions as “A health intervention is an act performed for, with or on behalf of a person or population whose purpose is to ass…
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Springer Nature
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2199-1154
- Electronic ISSN
- 2198-9788
- Latest issue on the website
- Volume 13, Issue 3 (September 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Drugs-Real World Outcomes
What CAS zone is Drugs-Real World Outcomes in?
In the 2025 upgraded edition of the CAS Journal Ranking, Drugs-Real World Outcomes is in Zone 4 of Medicine, and in Zone 4 of the minor category Pharmacology & Pharmacy. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Drugs-Real World Outcomes?
The journal's website gives an impact factor of 2 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 3.9, h-index 33.
How long does peer review take at Drugs-Real World Outcomes?
Authors report an average review time of about 8 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Drugs-Real World Outcomes?
According to the journal's author guidelines: Abstract: 150–250 words; Manuscript length: ≤ 10,000 words; Reference style: Numbered, in order of citation; Suggested reviewers: Optional. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Drugs-Real World Outcomes based?
Of the 39 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (12), Japan (5) and Australia (3). Counted from the institutions listed on the board page; for reference only.
Which databases index Drugs-Real World Outcomes?
According to LetPub and DOAJ records, Drugs-Real World Outcomes is indexed in ESCI, Scopus and DOAJ. The journal's website also lists Embase; that list has not been checked against each database.
Is Drugs-Real World Outcomes open access, and what is the APC?
Drugs-Real World Outcomes is a fully open-access journal. APC about USD 3,190.
Sources and updates
The facts on this page come from LetPub, OpenAlex, DOAJ, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .